The rise in direct-to-patient therapeutics access via online compounding pharmacies and other direct-to-patient sales models has increased the likelihood of patients utilizing medications alongside ...
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results